🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 for type 1 diabetes as adjunct — need advice Page 3

GLP-1 for type 1 diabetes as adjunct — need advice

SarahChen_PharmD Fri, Jan 31, 2025 at 10:02 PM 40 replies 1,803 viewsPage 3 of 8
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Feb 3, 2025 at 9:30 PM#11
Dr.LipidDallas said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Correct, and worth adding that it is reversible. Nothing being described here is a one-way door, which changes how cautious it is reasonable to be.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

17 17fiona_VT, denise_HTX, raj_cambridge and 14 others
Reply Quote Save Share Report
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Feb 6, 2025 at 11:14 AM#12
tony_orlando said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

This is exactly what I could not find anywhere else. Sending this to two other people who asked me the same thing last week.

16 16AttorneyGrant, DebRD_ATL, KristenIndy and 13 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Feb 9, 2025 at 12:57 AM#13
Dr.LipidDallas said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

Ask again with the specifics and you will get a better answer than this one.

Last edited: Feb 9, 2025 at 2:57 AM
15 15JessicaH_TX, KevinCompounds, TirzTom and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Feb 11, 2025 at 2:39 PM#14

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

That is the short version; the long version is somebody else's post.

14 14MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 11 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 14, 2025 at 4:19 AM#15

Moderator note: a couple of off-topic posts removed.

Last edited: Feb 14, 2025 at 8:19 AM
13 13PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 10 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register